To compare the efficacy and impact on sexual function of combination of Tadalafil and Tamsulosin versus Tamsulosin alone in the management of Benign prostatic hyperplasia in patients attending Lagos State University Teaching Hospital

Outcome measures of Tadalafil-Tamsulosin combination therapy versus Tamsulosin alone in the management of benign prostate hyperplasia in patients attending Lagos State University Teaching Hospital.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202311592558473

Enrollment

182

Registered

2023-11-29

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

Tadalafil Tamsulosin combination therapy

Tamsulosin Alone

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients must be 45 years and above with mild to moderate IPSS (0-19) Patients with PSA less than or equals 4ng/ml, normal DRE and imaging studies Patients with peak flow rate less than 15mls/sec and PVR greater than or equals 50mls Patients who give verbal and written consent to the study

Exclusion criteria

Exclusion criteria: Patients with severe IPSS, PSA greater than 4ng/ml and peak flow rate greater than 15mls/sec. Patients with PVR less than 50mls. Contraindications to study medications. Patients with no sexual partner during the study period

Design outcomes

Primary

Measure	Time frame
International prostatic symptoms score	—

Secondary

Measure	Time frame
Quality of life, erectile function, maximum urinary flow rate and post-void residual urine volume	—

Countries

Nigeria

Contacts

Public ContactClement Akinsola

Data Analyst

ceefourme@gmail.com2348174226011

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026